Article · 29 Jun 2026
Research articlePublished 25 Nov 2013
Bioburden vs. Antibiogram of Diabetic Foot Infection
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Proper management of diabetic foot infection requires appropriate selection of antimicrobials based on culture and antimicrobial susceptibility testing. The aim was to determine the optimal antimicrobial susceptibility to various commonly used antimicrobials for Gram Positive Cocci (GPCs) and Gram Negative Bacilli (GNBs) in patients with type 2 diabetes and foot infection and also to find out the percentage of MRSA (Methicillin Resistant Staphylococcus aureus) and ESBL (Extended Spectrum of Beta-Lactamase)-producing pathogens and their susceptibility pattern. Materials and methods: A total of 961 (M: F 697: 264) patients with type 2 diabetes and foot infection were included in this study. After surgical debridement, pus and tissue samples were collected under aseptic conditions in sterile containers and subjected to microbiological analyses. Gram’s staining, culture and sensitivity test were done along with quality control procedures. Results: Among 961 subjects, single pathogens were isolated in 65.3%, poly-microbial organisms were isolated from 14.3% and 20.4% had sterile cultures. A total of 892 pathogens were isolated, of which 41.1% were GPCs, 57.7% were GNBs and 1.1% were Candida Spp. Imipenem showed the highest sensitivity of more than 95% and Amikacin above 70% against both GPCs and GNBs. Beta-lactam/beta-lactamase inhibitors showed more than 60% sensitivity to GNBs. GPCs were also >75% susceptible to doxycycline, 99.4% sensitive to vancomycin, 89.1% to linezolid, >55% to clindamycin and erythromycin. 1.35% of MRSA and 3.12% of ESBL were isolated from foot ulcers. Conclusions: In conclusion, Imipenem was found to be the most potential antimicrobial against both GPCs, and GNBs. Among the combinations, cefipime-tazobactum and cefoperazone-sulbactum was the best choice. Anti-MRSA antimicrobials, linezolid and vancomycin and Anti-ESBLs like Imipenem and meropenem can be given to patients producing MRSA or ESBL.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Research on Foot & Ankle.
Research article · 31 Jan 2026
Bimalleolar Equivalent Ankle Fracture Joint Contact: Comparison of Two Stabilization Methods
Commentary · 11 Oct 2025
Is Diabetic Foot Ulcer Healing Enough
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Research on Foot & Ankle
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Janifer Jasmine”
- BylineArticles whose byline prints “Geethalakshmi Sekkizhar”
- BylineArticles whose byline prints “Satyavani Kumpatla”
- BylineArticles whose byline prints “Vijay Viswanathan”